Author Index—1997

Abdel-Davem, HM, 141(ab)
Abdel-Dayem, E, 141(ab)
Ackermann, RJ, 137(ab)
Adler, LP, 115
Afriyie, MO, 152(ab)
Ahlberg, AW, 136(ab)
Akisik, MF, 141(ab)
Alazraki, NP, 144(ab), 153(ab)
Alvarez-Diez, T, 156(ab)
Amin, KC, 49
Arias, JM, 110
Arroyo, A, 151(ab), 151(ab)

Badich, JW, 141(ab)
Bares, R, 143(ab)
Barker, C, 154(ab)
Barlow, RV, 150(ab)
Baron, J, 137(ab)
Barrow, SA, 141(ab), 143(ab)
Bartolomei, M, 191
Bavaria, G, 142(ab), 149(ab)
Benjamin, C, 142(ab), 149(ab)
Bennett, WF, 148(ab)
Beven, T, 291
Beyer, T, 146(ab)
Bolus, NE, 120
Brisebois, J, 142(ab)
Brown, TF, 98
Buijs, WCAM, 142(ab)
Burns, B, 151(ab), 151(ab)
Burris, T, 152(ab)
Buscombe, JR, 140(ab), 150(ab)

Caldwell, CB, 201
Cao, ZJ, 187
Caravalho, J, Jr, 55
Carrasquillo, JA, 154(ab)
Casey, CE, 139(ab)
Cason, R, 269
Chang, CP, 137(ab)
Chang, SL, 147(ab)
Chen, ZP, 149(ab)
Cheng, KT, 44
Cheung, AK, 110
Chinol, M, 191
Chou, KL, 137(ab), 147(ab)
Chowdhury, S, 144(ab), 155(ab)
Clapp, DA, 151(ab)
Clarke, KG, 264
Connor, AM, 73
Corrigan, P, 140(ab), 140(ab), 144(ab), 153(ab)
Corstens, FHM, 142(ab)
Coupal, JJ, 148(ab), 148(ab), 149(ab),195
Cremonesi, M, 191
Cronin, V, 66, 152(ab), 293(ed)
Cross, DM, 136(ab), 151(ab), 151(ab)
Crosthwaite, MH, 73
Cutrera, PF, 147(ab), 147(ab)
Cwikla, JB, 140(ab), 150(ab)

Dachille, MA, 146(ab)
Dalipaj, MM, 156(ab)
Das, S, 269
De Cicco, C, 191
Dell, MA, 12
DeMan, P, 137(ab)
Denhartog, P, 150(ab)
DePaul, R, 141(ab)
Derbyshire, SWG, 146(ab)
Deutsch, G, 141(ab)
Dobbeleir, A, 150(ab)
Dohmen, BM, 143(ab)
Dowd, SB, 24, 86, 120, 171, 246
Driver, DR, 272
Dunn, RM, 18
Dunnwald, LK, 106
Durick, D, 24, 86

Eastman, LK, 153(ab)
Eisenberg, B, 59
El-Zaftawy, H, 141(ab)
Elliott, DG, 138(ab)
Erb, DA, 142(ab), 143(ab)
Eshima, D, 152(ab), 153(ab)
Eshima, L, 152(ab), 153(ab)

Fahey, FH, 139(ab)
Fain, RL, 154(ab), 155(ab)
Fang, P, 149(ab)
Farrell, E, 142(ab)
Faulhaber, PF, 115
Ficaro, EP, 137(ab)
Fiorenza, M, 191
Fischman, AJ, 141(ab), 143(ab)
Folks, R, 140(ab), 140(ab)
Forstrom, LA, 144(ab)
Fossatti, AT, 136(ab), 151(ab)
Fry, J, 138(ab), 145(ab), 148(ab)
Fry, JP, 205
Frye, JL, 137(ab)
Fujinaga, T, 181
Funahashi, M, 136(ab)

Gagnon, A, 142(ab), 149(ab)
Galantowicz, P, 66, 152(ab)
Galt, JR, 144(ab), 153(ab)
Garcia-Pena, E, 55
Gear, A, 151(ab)
Gibbons, DL, 139(ab)
Gilbert, S, 1, 83, 169, 243
Gillan, ER, 151(ab)
Glynn, RB, 155(ab)
Go, RT, 49
Goldenberg, DM, 18
Gona, J, 152(ab)
Gonzalez, C, 152(ab)
Goodman, M, 152(ab)
Grant, SF, 144(ab), 153(ab)
Grant, YD, 150(ab)
Greene, J, 70(le)
Griffith, S, 238
Groch, MW, 147(ab), 147(ab), 155(ab)
Gwilliam, RW, 153(ab)

Hackett, MT, 41, 146(ab), 148(ab), 148(ab), 149(ab), 195
Hahn, K, 154(ab)
Halama, JR, 155(ab)
Halkar, RK, 144(ab), 153(ab)
Harkness, BA, 139(ab)
Harris, AJ, 137(ab)
Hartnett, SD, 106
Haseman, MK, 143(ab)
Heller, GV, 37, 136(ab), 151(ab), 151(ab)
Helsabeck, C, 144(ab)
Hendel, RC, 147(ab)
Henkin, RE, 155(ab)
Herbst, J, 79, 232, 289
Herda, SC, 144(ab)
Herold, TJ, 138(ab)
Hilson, AJW, 140(ab), 150(ab)
Hinkle, GH, 138(ab), 145(ab), 148(ab), 205
Hladik, WB, III, 70(le)
Hoffmann, J, 143(ab)
Homs, CJ, 138(ab), 140(ab)
Humphries, JK, 44
Hung, JC, 138(ab), 142(ab), 144(ab), 155(ab), 155(ab), 157(ab)
Hutchins, GD, 154(ab), 155(ab)

Ichise, M, 150(ab)
Intenzo, C, 144(ab), 153(ab)
Izumi, K, 136(ab)

Jansson, A, 156(ab)
Johnson, R, 152(ab)
Johnston, DL, 155(ab)
Juweid, M, 18

Kairys, J, 144(ab)
Kaplan, DD, 264
Kaplan, MS, 218
Kashiyama, K, 136(ab)
Kelty, N, 187
Keyes, JW Jr., 139(ab)
Kida, T, 256
Kim, S, 144(ab), 153(ab)
Kinahan, PE, 146(ab)
King, AL, 157(ab)
Komiyama, N, 181
Kosegi, JE, 146(ab)
Kothapalli, S, 157(ab)
Kozar, JJ, 144(ab)
Kreis, JM, 147(ab)
Krishnamurthy, GT, 147(ab)
Krzos, JR, 155(ab)
Kwan, D, 150(ab)

Lamatrice, RA, 138(ab), 205
Larsen, TW, 153(ab)
Leifer, ES, 55
Leisure, GP, 115, 141(ab)
Leonard, SM, 147(ab)
Leonardi, L, 191
Leveque, F, 152(ab)
Levine, MG, 136(ab), 151(ab)
Lietzenmayer, R, 143(ab)
Lin, HM, 137(ab)
Liu, A, 264
Liu, HG, 141(ab)
Liu, RS, 137(ab), 147(ab)
LoBuglio, AF, 138(ab)
Loesch, JA, 205
Lopatin, G, 264
Lou, JQ, 141(ab)

Macey, DJ, 138(ab)
Machida, S, 136(ab)
Mack, DR, 139(ab)
MacMullan, J, 139(ab)
Madras, BK, 141(ab)
Magoun, S, 261
Magoun, SL, 41, 146(ab)
Mankoff, DA, 106
Manthei, DA, 146(ab)
Markand, O, 155(ab)
Martin, S, 139(ab)
Maruno, H, 181
Mascitelli, VA, 37
Masdeu, J, 141(ab)
Massler, J, 269
Masuda, K, 256
Matsuo, S, 256
McBride, JG, 138(ab), 140(ab)
McGill, CC, 151(ab)
McKay, BF, 52, 149(ab)
Meltzer, CC, 146(ab), 146(ab)
Mento, C, 269
Meredith, RF, 138(ab)
Merlino, D, 70(le)
Merry, ML, 144(ab)
Meyers, A, 275
Mihara, K, 136(ab)
Milko, DL, 146(ab)
Miller, M, 72, 73, 126, 220, 287
Miraldi, F, 115, 141(ab)
Mishkin, F, 156(ab), 157(ab), 157(ab)
Mitchell, B, 261
Morita, R, 256
Morris, RS, 37
Morton, KA, 110
Mountz, JM, 141(ab)
Mullan, BP, 138(ab), 142(ab), 144(ab), 155(ab)
Muller-Berg, M, 143(ab)
Murata, H, 181
Murphy, D, 127

Nabi, HA, 66, 142(ab), 143(ab), 152(ab)
Naddaf, S, 141(ab)
Navaratnam, T, 156(ab)
Ng, CK, 148(ab)
Nguyen, K, 156(ab)
Nichols, D, 79, 129, 235, 290
Noma, K, 256

O'Connell, R, 141(ab)
O'Donnell, JK, 115, 141(ab)
Odom-Maryon, TL, 264
Ohnishi, H, 256
Olsen, JO, 138(ab), 148(ab), 205
Omar, W, 141(ab)
Onoguchi, M, 181
Oswald, WM, 142(ab), 157(ab)
Ota, T, 256
Owens, TP, 155(ab)

Paberzs, AV, 137(ab)
Paganelli, G, 191
Palestro, CJ, 152(ab)
Parsa, M, 141(ab)
Patel, J, 144(ab), 153(ab)
Patel, P, 151(ab), 151(ab)
Patton, JA, 153(ab)
Perdikaris, N, 195
Pham, HL, 156(ab), 157(ab), 157(ab)
Pickett, M, 3, 84
Pickett, MW, 146(ab)
Pisani, DE, 110
Polulak, D, 152(ab)
Porter, DV, 138(ab)
Pozderac, RV, 148(ab)
Prekeges, J, 124
Prekeges, JL, 59
Prisco, G, 191

Randolph, T, 272
Raubitschek, AA, 264
Reed, NL, 143(ab)
Reid, RD, 145(ab)
Rich, DA, 4, 148(ab)
Rickabaugh, LE, 139(ab)
Rose Wolf, GE, 152(ab)
Rosner, D, 143(ab)
Rossi, B, 139(ab)
Ruddy, TD, 156(ab)
Russell, A, 37, 136(ab), 151(ab), 151(ab)
Ruszkiewicz, JA, 146(ab)
Ryo, UY, 261

Saha, GB, 49
San Pedro, EC, 141(ab)
Sandler, MP, 153(ab)
Sayed, MG, 217
Scheff, AM, 144(ab)
Schmitt, MA, 137(ab)
Schraml, FV, 272
Schwenzer, N, 143(ab)
Scott, JW, 76, 222
Seibyl, J, 139(ab)
Seldin, DW, 139(ab), 151(ab)
Seo, IS, 138(ab), 140(ab)
Shah, S, 147(ab)
Sharkey, RM, 18
Shehata, AR, 37
Shih, W-J, 146(ab), 261
Shimizu, R, 131(ab)
Shodavaram, S, 269
Shone, MD, 153(ab)
Shonibi, YI, 138(ab)
Shonubi, YI, 140(ab)
Silverman, ED, 272
Sinusas, AJ, 137(ab)
Smith, EM, 124
Smith, EO, 139(ab)
Smith, KF, 138(ab), 140(ab)
Smith, WJM, 128
Soso, MJ, 146(ab)
Soufer, R, 148(ab)
Spanaki, M, 139(ab)
Spencer, SS, 139(ab)
Spicer, JA, 70(le)
Spicer, KM, 44
Spies, SM, 52, 147(ab), 147(ab), 149(ab)
Spies, WG, 147(ab)
Stallings, LE, 44
Stein, K, 154(ab)
Steves, AM, 24, 86, 171, 246
Stipp, VH, 146(ab)
Sullivan, A, 290, 290
Surrel, S, 81, 130
Swailem, FM, 147(ab)
Sy, WM, 138(ab), 140(ab)
Sze, P, 138(ab), 140(ab)
Taillefer, R, 142(ab), 149(ab)
Takada, M, 256
Takayama, T, 181
Tatsch, K, 154(ab)
Taylor, A, 140(ab), 140(ab), 144(ab)
Thakrar, DS, 140(ab), 150(ab)
Thomas, K, 170, 244
Thomas, KS, 146(ab)
Thompson, RB, 41
Tomas, MB, 152(ab)
Top, L, 154(ab)
Townsend, DW, 146(ab), 146(ab)
Tually, PJ, 154(ab)

Urso, GK, 146(ab)

Valdivia, S, 110
Valdivia, V, 157(ab)
van den Broek, WJM, 142(ab)
Van Heertum, RL, 269
Vandermeiren, R, 150(ab)
Vandevivere, J, 150(ab)
Vervaet, A, 150(ab)
Vesselle, HJ, 115
Vines, D, 150(ab)

Wackers, FJT, 137(ab)
Waldmann, T, 154(ab)
Walsh, TK, 147(ab)
Wan, WX, 149(ab)
Wang, BC, 149(ab)
Wang, TST, 269
Waterstram-Rich, KM, 146(ab)
Watkins, JW, III, 55
Watson, WR, 137(ab)
Whatley, M, 154(ab)
White, J, 154(ab)
White, MP, 37, 136(ab), 151(ab), 151(ab)
Whiting, JH, Jr, 110
Wiegner, R, 44
Wieseler, JF, 139(ab)
Willey, LM, 137(ab)
Williams, BS, 138(ab), 205
Williams, LE, 264
Wintch, K, 275
Wiseman, GA, 139(ab)
Wiseman, MB, 146(ab)
Wisniewski, G, 139(ab)
Wolf, GER, 152(ab),
Wong, JYC, 264
Wu, CY, 149(ab)
Wu, LC, 137(ab)

Yamamoto, I, 256
Yasillo, NJ, 98
Yeh, SH, 137(ab), 147(ab)

Zhang, J, 153(ab)
Zhou, X, 149(ab)
Zimmer, AM, 52, 147(ab), 149(ab)
Zubal, IG, 137(ab), 139(ab)

Subject Index—1997

A

Abdomen, ^{18}F-FDG PET imaging improvements, pelvis, 115
Absorbed dose, estimating residence times and associated errors in calculations, ^{90}Y, 264
Accelerator-produced isotopes, Department of Energy research funding, 131
ACNP, Address change, 238
AECB, *see* Anatomic Energy Control Board
Alzheimer's disease, caring for the older patient, value of nuclear medicine, 246
Artifacts
frame loss, myocardial perfusion imaging, 152(ab)
nonuniform, syringe needle used as point-source during acquisition of intrinsic quality-control flood, 41
photon deficient, caused by metallic plates, brain SPECT, 146(ab)
third foot sign, simultaneous dual isotope acquisitions, 152(ab)
Atomic Energy Control Board (AECB), Canada approves Maple reactor plan, 239
Attenuation, increased counts in fanbeam collimation, SPECT, 187
Attenuation correction
analytic and measured, PET brain imaging, 139(ab)
body habitus impact standardized, correlation with cardiac catheterization, 136(ab)
PET, comparison of 2D and 3D whole body, 146(ab)
transmission-emission SPECT system, quality control, 137(ab)
Author guidelines, 294
Automated synthesis unit, ^{18}F-FDG production by, 152(ab)

B

Beta radiation, incidence of delayed esophageal passage, orogastric transit of ^{131}I capsules, 55
Blood contamination, commercially prepared radiopharmaceuticals, lead pigs, effect of protective inserts, 146(ab)
Blood sampling, automated, closed-recirculation loop, for PET, 147(ab)
Bone
imaging, uniplanar fanbeam collimators, 140(ab)
mineral density, DEXA spine measurements, elderly patients, 153(ab)
Book review
MRI Basic Principles and Applications, 217
MRI for Technologists, 217
Numerical Recipes in Fortran 90: The Art of Parallel Scientific Computing, 2nd Ed., Vol. 2 of Fortran Numerical Recipes, 218
Review of Nuclear Medicine Technology, 2nd ed., 124
Single-Photon Emission Computed Tomography: A Primer, 3rd ed., 124
Technical Magnetic Resonance Imaging, 217
Brain
perfusion
^{99m}Tc ECD and HMPAO imaging comparison, 141(ab)
psychiatric population, ^{15}O water PET, 141(ab)
tumor, SPECT, ^{201}Tl and ^{99m}Tc-MIBI comparison, 153(ab)
Breast cancer
^{99m}Tc-sestamibi scintimammography, usefulness and reproducibility of semiquantitative analysis, 106
acquisition protocol for imaging with ^{99m}Tc synthetic peptide and ^{99m}Tc-MDP, 191
chest wall lesions, posterior oblique views, 157(ab)
diagnosis, scintimammography with and without masking, 157(ab)
prone versus supine imaging, CEA-SCAN, 143(ab)
Breast imaging, ^{99m}Tc-sestamibi scintimammography, utility and reproducibility of semiquantitative analysis, 106
Bremsstrahlung imaging, ^{90}Y monoclonal antibody, image restoration effects, 154(ab)

C

Camera systems
Anger, quantitative imaging, ^{177}Lu, 138(ab)
efficient use of, changing health care environment, 137(ab)
Cancer, imaging with radiolabeled antibodies, 18
Carcinoembryonic antigen (CEA), cancer imaging with radiolabeled antibodies, immunoscintigraphy, 18
CEA, *see* Carcinoembryonic antigen
Cerebrovascular disease
caring for the older patient, value of nuclear medicine, 246
quantification of regional cerebral blood flow, ^{133}Xe SPECT, 141(ab)
Certification, of nuclear medicine technologists, 71(le)
Chapter officer update, 231
Chromatography methods
quality control of ^{99m}Tc-bicisate, 49
rapid miniaturized system for ^{99m}Tc-tetrofosmin, quality control, 52
Cine viewing, dynamic acquisition, use in pediatric nuclear imaging, 150(ab)
Circular versus noncircular acquisition, clinical comparison using ^{99m}Tc myocardial SPECT imaging, 37
Closed-recirculation loop, automated blood sampling, for PET, 147(ab)
Coincidence imaging
^{18}F-FDG, dual-head scintillation camera, 153(ab)
gamma camera, NaI(Tl) crystals, 155(ab)
Collimators
ADAC vertex, ^{99m}Tc myocardial perfusion imaging, 151(ab)
fanbeam, skeletal imaging, 140(ab)
Colorectal cancer, tumor measurement, PET with ^{18}F-FDG, 152(ab)
Communication, caring for the older patient, ethical issues, 171
Compounding, legislation introduced in Congress, 129
Computers, camera systems, efficient use in changing health care environment, 137(ab)
Contamination monitoring, gamma camera-based system for wipe testing, radiation safety, 201
Contrast agents, ^{99m}Tc-labeled, excluding artifact in myocardial SPECT, 136(ab)
Critical thinking, dichotomous conclusions, relation to nuclear medicine technology, 120
Cutoff frequency, SPECT images of myocardial perfusion in a one-day protocol, normalized mean square error, 256
Cyclosporine, effect on labeling efficiency, ^{99m}Tc tagged red blood cells, 70(le)

D

Death and dying, caring for the older patient, ethical issues, 171
Decision making
caring for the older patient, ethical issues, 171
dichotomous thinking, professional practice, 120
Dipyridamole, retrospective comparative study of changes in cardiac stress testing, ^{99m}Tc-sestamibi, ^{99m}Tc-tetrofosmin, 275
Dose calibrator, correction factors for, ^{89}Sr solutions used in, 148(ab)
Dosimetry, ^{90}Y-labeled monoclonal antibodies, 147(ab)
Dual-energy x-ray absorptiometry, spine bone mineral density measurements, elderly patients, 153(ab)
Dynamic acquisition, cine viewing, use in pediatric nuclear imaging, 150(ab)

E

Editor's Page
age-specific competencies, 1(ed)
annual meeting, 83(ed)
Index Medicus, *JNMT* inclusion, 169(ed)
recognition of contributors, *JNMT*'s 25th anniversary, 243(ed)
Ejection fraction, measurement with ^{99m}Tc-sestamibi gated SPECT, collimator and filter selection effects, 149(ab)
Electrocardiogram-gated SPECT imaging, compared to ungated SPECT imaging, comparison of regional myocardial uptake, ^{99m}Tc-MIBI, 181
Enterogastric reflux, mimicking gallbladder disease, hepatobiliary imaging, 151(ab)
Epilepsy
effective and versatile administration of radiopharmaceuticals, 138(ab)
ictal brain imaging
^{99m}Tc, 142(ab)

seizure foci, localization, brain SPECT, 139(ab)
Euthanasia, caring for the older patient, ethical issues, 171

F

Facility design, radiation safety, reducing exposure in PET centers, 98
Fanbeam collimation, effects of photon attenuation, SPECT, 187
FDA Commissioner, ACNP and SNM recommend Randy P. Juhl, PhD, 129
First-pass studies, combined with multigated acquisition studies, ^{99m}Tc-RBC labeling, 44
Fluorine-18-FDG
coincidence imaging of, dual-head scintillation camera, 153(ab)
development of protocol PET, 66
imaging improvements of the abdomen and pelvis, PET, 115
oral clinical PET, brain, 137(ab)
PET versus SPECT, myocardial tissue viability, 272
production, automated synthesis unit, 152(ab)
tumor measurement, colorectal cancer, 152(ab)

G

Gamma camera
dual-head, simultaneous quality control of both detectors, 150(ab)
PET versus SPECT, determining myocardial tissue viability, ^{18}F-FDG, 272
routine imaging, NaI(Tl) crystals, 155(ab)
triple-headed, ^{133}Xe brain SPECT, 154(ab)
Generator, ^{99}Mo system, increased weight of, 149(ab)
Geometric averaging, opposing views, dual-detector camera, split renal function assessed with, 140(ab)
Geriatric assessment, caring for the older patient, 171
Geriatrics
age-related anatomic and physiologic changes and pathologies, nuclear medicine adaptations, 86
caring for the older patient
ethical issues, 171
relating theory to practice, meeting age-specific needs, 24
value of nuclear medicine, 246
Gerontology
age-related anatomic and physiologic changes and pathologies, nuclear medicine adaptations, 86
ethical issues, 171
theories of aging
age-specific competencies, JCAHO accreditation, 24
Glomerular filtration rate, determining by plasma clearance of ^{99m}Tc-DTPA, patients with differing degrees of renal function, ^{125}I-iothalamate, 110
Glycoprotein IIb/IIIa receptors, ^{99m}Tc P280 binding to, detection of acute deep venous thrombosis, 147(ab)
Government Relations Committee, February meeting, 129
Grief, caring for the older patient, ethical issues, 171

H

Heart
function, left ventricular defected mass, left ventricle ejection fraction comparison, 156(ab)
simultaneous dual isotope ^{18}F/^{99m}Tc SPECT imaging, defect size in, 137(ab)
History of PET, development as a diagnostic tool, instrumentation
Michel Ter-Pogossian, 4
Hypotonic lysis, radiolabeled leukocytes with, 144(ab)

I

Image co-registration, subtraction technique comparison
FDG PET serial brain tumor imaging, 154(ab)
interictal and ictal HMPAO SPECT, 155(ab)
Image fusion, CT and ^{111}In pentetreotide SPECT, in neuroendocrine tumors, 148(ab)
Image processing techniques, ^{111}In capromab pendetide images, prostate cancer, 138(ab)
Immunoscintigraphy
^{111}In capromab pendetide images, prostate cancer, 138(ab)
cancer imaging with radiolabeled antibodies, 18
Index Medicus, *JNMT* inclusion, 169(ed), 238
Indium-111 capromab pendetide, technical considerations for quality imaging, prostate cancer, 205
Indium-111 pentetreotide, SPECT, image fusion in, neuroendocrine tumors, 148(ab)
Informed consent, caring for the older patient, ethical issues, 171
Instrumentation, history of PET as a diagnostic tool, 4
Iodine-123 altropane, SPECT, evaluation of Parkinson's disease, 141(ab)
Iodine-123-sodium iodide, parathyroid imaging, 59
Iodine-125-iothalamate, glomerular filtration rate determination using ^{99m}Tc-DTPA, patients with differing degrees of renal function, 110
Iodine-131, therapy, thyroid cancer, process for safe and efficient care, 145(ab)
Iodine-131-MIBG, radiotherapy, safety measures with children, 142(ab)

J

JNMT, 25 years of excellence, outstanding papers, 279
Joint Review Committee on Educational Programs in Nuclear Medicine Technology, 76, 222
JRCNMT, *see* Joint Review Committee on Educational Programs in Nuclear Medicine Technology

K

Kidney
function, assessment on a dual-detector camera, geometric averaging, 140(ab)
plasma flow, off-site determination with ^{99m}Tc MAG3, 150(ab)
^{99m}Tc MAG3 clearance, external probe for monitoring, 140(ab)

L

Leadership mentoring, Message from the President, 84
Leukocytes
radiolabeled, hypotonic lysis method, 144(ab)
^{99m}Tc exametazime-labeled, distribution of cell-bound activity, 155(ab)
Lung, ventilation-perfusion scans, SPECT, 139(ab)
Lymph nodes
metastases detection, head and neck squamous-cell carcinoma, FDG PET, 143(ab)
sentinel, localization using ^{99m}Tc serum albumin, primary melanoma, 144(ab)
Lymphoma, cancer imaging with radiolabeled antibodies, 18
Lymphoscintgraphy
sentinel lymph node localization using ^{99m}Tc serum albumin, primary melanoma, 144(ab)
^{99m}Tc sulfur colloid, selective lymphadenectomy, malignant melanoma, 144(ab)
^{99m}Tc sulfur colloid, stability in, 153(ab)

M

Melanoma
malignant, ^{99m}Tc sulfur colloid lymphoscintigraphy, 144(ab)
primary, sentinel lymph node localization using ^{99m}Tc serum albumin, 144(ab)
Mental competency, caring for the older patient, ethical issues, 171
Message from the President, 170
collaboration between professional organizations, 244
leadership mentoring, 84
membership, 3
Migraine headache, pathophysiology, PET use in, 146(ab)
Miniaturized chromatography system, rapid radiochemical purity results for ^{99m}Tc-tetrofosmin preparations, quality control, 52
Molybdenum-99 generator system, increased weight of, 149(ab)
Monoclonal antibodies
ProstaScint®, technical considerations, 143(ab)
residence times and errors in patient absorbed-dose calculation, ^{90}Y, 264
^{90}Y-labeled, dosimetry, 147(ab)
Multigated acquisition, combined with cardiac first-pass studies, ^{99m}Tc-RBC labeling, 44
Myocardial infarction, left ventricular defected mass, left ventricle ejection fraction comparison, 156(ab)
Myocardial perfusion imaging
frame loss artifacts, single- and dual-headed systems, 152(ab)
prefilter cutoff frequencies needed in one-day protocol, SPECT, 256
^{99}Tc, ADAC vertex collimator for, 151(ab)
^{99m}Tc-labeled contrast agent for, excluding artifact in myocardial SPECT, 136(ab)
^{99m}Tc NOEt, preclinical pharmacology study, 149(ab)
Myocardial perfusion study, exercise to assist subscriber, interpretation of findings, 238

Myocardial SPECT imaging, circular versus noncircular acquisition, ^{99m}Tc-sestamibi, 37
Myocardial viability, PET versus SPECT, ^{18}F-FDG, 272

N

Neuroendocrine tumors
CT and ^{111}In-pentetreotide SPECT, image fusion of, 148(ab)
imaging
4-hour octreoscans, 144(ab)
^{99m}Tc P829, 142(ab)
NMTCB, *see* Nuclear Medicine Technology Certification Board
Nonuniformity, intrinsic flood artifact, point-source syringe needle, 41
Normalized mean sqare error, prefilter cutoff frequencies needed, SPECT images of myocardial perfusion in a one-day protocol, 256
NRC, *see* Nuclear Regulatory Commission
Nuclear cardiology, caring for the older patient, value of nuclear medicine, 246
Nuclear medicine, mobile, technical aspects, 155(ab)
Nuclear medicine technology, advances within health care field, 127
Nuclear Medicine Technology Certification Board (NMTCB)
employment and salary survey results, 73
report from chair, 72, 287
report on competency, FDA standards, recertification exams, 126
report on SNM annual meeting, computer adaptive testing (CAT), 220
World Wide Web debut, 238
Nuclear oncology, caring for the older patient, value of nuclear medicine, 246
Nuclear Regulatory Commission (NRC)
patient release criteria, 130
radionuclide air emissions, 80
reform, 290
strategic assessment, 235

O

Octreotide scans, neuroendocrine tumors, 144(ab)
Oncology
development of FDG protocol
^{18}F-FDG PET, 66
FDG PET and SPECT comparison, 143(ab)
Orogastric transit, esophageal passage of ^{131}I capsules, beta radiation, 55
Outstanding papers, 25 years of excellence, *JNMT* award-winning contributions from 1973 through 1996, 279

P

Parathyroid imaging, ^{201}Tl-chloride, ^{99m}Tc-pertechnetate, ^{99m}Tc-sestamibi, ^{123}I-Na iodide, 59
Parkinson's disease, ^{123}I altropane SPECT evaluation of, 141(ab)
Pathology, age-related anatomic and physiologic changes, tailoring nuclear medicine procedures, 86
Patient release criteria, NRC ruling, 130
Pediatrics
nuclear imaging, dynamic acquisition and cine viewing in, 150(ab)
radiation safety measures, treatment with high dose ^{131}I-MIBG, 142(ab)
Pelvis, ^{18}F-FDG PET imaging improvements, abdomen, 115
PET, *see* positron emission tomography
PET isotopes, radiation safety for 511-keV emitters, positron shielding, 12
Phantoms
American College of Nuclear Physicians Proficiency Testing Program, 81, 131, 238, 291
monoclonal antibody imaging, gallium, 238
Pharmacological stress testing, retrospective comparative study of changes in nuclear medicine, cardiac patients, 275
Platelets, radiolabeling, ^{99m}Tc-HMPAO, optimization of, 156(ab)
Positioning, prone versus supine, breast cancer imaging, 143(ab)
Positron emission tomography (PET)
brain
analytic and measured attenuation correction in, 139(ab)
oral ^{18}F-FDG, 137(ab)
caring for the older patient, value of nuclear medicine, 246
development of protocol
^{18}F-FDG, 66
FDA regulations, petition to stay effective date, 130
FDG
comparison with SPECT in oncology, 143(ab)
preoperative lymph node staging, head and neck squamous cell carcinoma, 143(ab)
serial brain tumor imaging, 154(ab)
^{18}F-FDG imaging improvements, abdomen and pelvis, 115
global sensitivity, prolonged absence of radioactivity effects, 148(ab)
history, 4
migraine headaches, 146(ab)
^{15}O water, quantitative brain perfusion in psychiatric population, 141(ab)
radiation safety concerns, reducing exposure, facility design, 98
2D and 3D whole-body, comparison, ECAT HT+, 146(ab)
Positron emissions, PET versus SPECT, determining myocardial tissue viability, ^{18}F-FDG, 272
Positron shielding, radiation safety for 511-keV emitters, 12
Procedure guidelines, SNM distribution, 26 approved for practice, 128
Professional practice, critical thinking in nuclear medicine technology, dichotomy, 120
Proficiency testing
ACNP news, 130
computer adaptive testing, NMTCB, 238
ProstaScint®, technical considerations for ^{111}In capromab pendetide images, prostate cancer, 205
Prostate cancer
acquiring and processing ^{111}In capromab pendetide images, technical considerations, ProstaScint®, 205
^{111}In capromab pendetide images, technical considerations, 138(ab)
ProstaScint® use in, technical considerations, 143(ab)

Q

Quality assurance, 25 years and counting, 238
Quality control
dual-head gamma camera, single close point source, 150(ab)
effects of sequential reagent addition on ^{99m}Tc-RBC labeling efficiency, UltraTag® kit, 269
nonuniformity intrinsic flood artifact, 41
radiochemical purity
^{99m}Tc-sestamibi, paper chromatography systems for, 157(ab)
high-activity ^{99m}Tc-tetrofosmin, 149(ab)
rapid radiochemical purity results for ^{99m}Tc-tetrofosmin preparations, miniaturized chromatography, 52
^{99m}Tc-bicisate
rapid chromatographic method, 49
transmission-emission SPECT system, 137(ab)

R

Radiation monitoring, reducing exposure in PET centers, facility design, 98
Radiation safety
considerations for PET centers, facility design, 98
review for 511-keV emitters, positron shielding, 12
wipe tests with a conventional gamma camera, meeting regulatory requirements, 201
Radioactivity, prolonged absence of, global sensitivity of PET, 148(ab)
Radiochemical purity testing, rapid miniaturized chromatography, ^{99m}Tc-tetrofosmin, 52
Radioimmunodetection, cancer imaging with radiolabeled antibodies, 18
Radioimmunotherapy, estimating residence times, errors in patient absorbed-dose calculation, monoclonal antibody, 264
Radioiodine, incidence of delayed esophageal passage, orogastric transit of ^{131}I capsules, 55
Radioiodine pamphlet, new version to be released, 131
Radiopharmaceuticals
commercially prepared, blood contamination of lead pigs, effect of protective inserts, 146(ab)
preparation, safety factors, microwave oven, 148(ab)
Radiotherapy, ^{131}I-MIBG, safety measures with children, 142(ab)
Recertification, continued competency, NMTCB and proactive approach, 70(le)
Regional myocardial uptake, comparison between ECG-gated and ungated SPECT imaging, 181
Regions of interest, ^{99m}Tc-sestamibi scintimammography, utility and reproducibility of semiquantitative analysis, 106
Removable contamination, use of NaI well counter, ^{89}Sr, 195
Renal cell carcinoma, normal appearing ^{99m}Tc-DTPA renogram, case report, 261
Renal function, glomerular filtration rate determination using ^{99m}Tc-DTPA, ^{125}I-iothalamate, renography, 110
Renal imaging, normal renogram in renal cell carcinoma, ^{99m}Tc-DTPA, 261
Renography, glomerular filtration rate determination using ^{99m}Tc-DTPA, ^{125}I-iothalamate clearance, 110

Reproducibility studies, clearance, ^{99m}Tc MAG3, 140(ab)
Residence times, estimation of, errors in patient absorbed-dose calculation, radioimmunotherapy, 264

S

Scatter correction, ^{177}Lu, quantitative anger camera imaging, 138(ab)
Scintimammography
^{99m}Tc-sestamibi, comparison with multiple window imaging, 142(ab)
acquisition protocol, imaging with ^{99m}Tc synthetic peptide and ^{99m}Tc-MDP, breast cancer, 191
lateral prone views, versus anterior supine images, 150(ab)
posterior oblique views, detection of chest wall lesions in breast cancer, 157(ab)
with and without masking, diagnosis of breast cancer, 157(ab)
Self-study document, revision of application for accreditation, 222
Semiquantitative ratios, ^{99m}Tc-sestamibi breast imaging, regions of interest, 106
Sensitivity, effects of photon attenuation, increased counts in fanbeam collimation, SPECT, 187
Single-photon emission computed tomography (SPECT)
attenuation correction, standardized iterative reconstruction, 136(ab)
brain
^{201}Tl and ^{99m}Tc-MIBI comparison, 153(ab)
identification of photon deficient artifacts, 146(ab)
interictal and ictal HMPAO, 155(ab)
localization of epileptic seizure foci, 139(ab)
cardiac, ^{18}F scatter confounds estimation of defect size, 137(ab)
FDG, comparison with PET in oncology, 143(ab)
gated
collimators and filter selection effects, cardiac function, 149(ab)
left ventricular ejection fraction, reconstruction filter effects, 147(ab)
parallel hole, thyroid imaging, 151(ab)
photon attenuation, effects on increased counts in fanbeam collimation, sensitivity, 187
prefilter cutoff frequencies, myocardial perfusion imaging in one-day protocol, 256
transmission-emission, quality control, 137(ab)
ventilation-perfusion lung scans, technique, 139(ab)
SNM, *see* Society of Nuclear Medicine
SNM/ACNP government relations, 79, 129, 235
Society of Nuclear Medicine
annual meeting, 83, 133
election results, 224
SNM-TS meeting highlights, 224
Sodium iodide well counter, detecting ^{89}Sr removable contamination, 195
Somatostatin, Tc-labeled, imaging neuroendocrine tumors, 142(ab)
Squamous-cell carcinoma, head and neck, preoperative lymph node staging, FDG-PET, 143(ab)
Stannous chloride, effects of sequential reagent addition on ^{99m}Tc-RBC labeling efficiency, UltraTag® kit, 269
Stannous citrate, effects of sequential reagent addition on ^{99m}Tc-RBC labeling efficiency, UltraTag® kit, 269
Stroke, caring for the older patient, value of nuclear medicine, 246
Strontium-89
monitoring for removable contamination, use of NaI well counter, 195
solutions, determination of correction factors for dose calibrators, 148(ab)
Suicide, caring for the older patient, ethical issues, 171
Surface rendering, three-dimensional display, clinical utility of, 138(ab)

T

Technegas, radioactive contamination levels, occlusive face mask use in, 154(ab)
Technetium-99m, simultaneous dual-isotope acquisitions, artifact in, 152(ab)
Technetium-99m ECD
dosage management system, epilepsy, 138(ab)
ictal brain imaging, epilepsy, 142(ab)
^{99m}Tc-HMPAO comparison, brain perfusion imaging, 141(ab)
Technetium-99m MAG3
clearance
external probe for monitoring, 140(ab)
reproducibility studies, 140(ab)
effective renal plasma flow, off-site determination, 150(ab)
hepatobiliary excretion of, in routine renography, 151(ab)
Technetium-99m NOEt, myocardial imaging, preclinical pharmacology study, 149(ab)
Technetium-99m P280, binding to GP IIb/IIIa platelet receptors, detection of acute deep venous thrombosis, 147(ab)
Technetium-99m P829, imaging neuroendocrine tumors, 142(ab)
Technetium-99m pertechnegas, ventilation imaging with, 139(ab)
Technetium-99m red blood cell
effects of sequential reagent addition, proper labeling efficiency, UltraTag®, 269
labeling
combined cardiac first-pass and multigated acquisition studies, 44
Technetium-99m sulfur colloid
lymphoscintigraphy, selective lymphadenectomy in malignant melanoma, 144(ab)
stability, lymphoscintigraphy studies, 153(ab)
Technetium-99m synthetic peptide, acquisition protocol for breast cancer imaging, ^{99m}Tc-MDP, 191
Technetium-99m-bicisate, quality control, rapid chromatographic method, 49
Technetium-99m-DTPA
determining glomerular filtration rate by plasma clearance of, ^{125}I-iothalamate, 110
normal renogram in renal cell carcinoma, 261
Technetium-99m-HMPAO
exametazime-labeled leukocytes, distribution of cell-bound activity, 155(ab)
platelet radiolabeling using, optimization, 156(ab)
Tc-99m ECD comparison, brain perfusion imaging, 141(ab)
Technetium-99m-MDP, acquisition protocol for breast cancer imaging, ^{99m}Tc synthetic peptide, 191
Technetium-99m-pertechnetate, parathyroid imaging, 59
Technetium-99m-sestamibi
breast imaging, utility and reproducibility of semiquantitative analysis, 106
circular versus noncircular acquisition, myocardial SPECT imaging, 37
comparison of regional myocardial uptake between ECG-gated and ungated SPECT imaging, 181
parathyroid imaging, 59
preparation, safety factors, microwave oven, 148(ab)
prone immunoscintigraphy, comparison with multiple window imaging, 142(ab)
radiochemical purity determination, paper chromatography systems for, 157(ab)
retrospective comparative study of changes in cardiac stress testing, ^{99m}Tc-tetrofosmin, dipyridamole, 275
scintimammography, lateral prone views versus anterior supine images, 150(ab)
Technetium-99m-tetrofosmin
high-activity, radiochemical purity of, 149(ab)
rapid miniaturized chromatography, quality control, 52
retrospective comparative study of changes in cardiac stress testing, ^{99m}Tc-sestamibi, dipyridamole, 275
Technologist awards, SNM-TS meeting highlights, 224
Technologist committee chairs, list of chairpersons, 229
Technologist executive committee members, list of executive members, 229
Thallium-201-chloride, parathyroid imaging, 59
Theories, aging, 24
Three-dimensional display, clinical utility of, 138(ab)
Thyroid, imaging, parallel hole SPECT, 151(ab)
Thyroid cancer, radioiodine therapy, process for safe and efficient care, 145(ab)
Treadmill exercise testing, retrospective comparative study of changes in cardiac stress testing, ^{201}Tl, ^{99m}Tc-sestamibi, ^{99m}Tc-tetrofosmin, dipyridamole, 275
Tribute to a colleague, 293

U

UltraTag®, effects of sequential reagent addition, ^{99m}Tc-RBC labeling efficiency, quality control, 269

V

Ventilation-perfusion scans, lung
SPECT, 139(ab)
^{99m}Tc pertechnegas, 139(ab)
Ventricular function
gated SPECT, reconstruction filter effects, 147(ab)
pediatric oncology patients, in vitro labeling for prechemotherapy assessment, 151(ab)
Ventriculography, radionuclide, prechemotherapy assessment, pediatric oncology patients, 151(ab)
Verification of Involvement in Continuing Education (VOICE)
approved continuing education programs, Ask Michele, 232
guidelines, 233
VOICE, *see* Verification of Involvement in Continuing Education

W

Wiener restoration filter, Bremsstrahlung imaging, ^{90}Y monoclonal antibody, 154(ab)
Wipe tests, gamma camera-based system, meeting regulatory requirements for contamination monitoring, 201

X

Xenon-133 SPECT
brain, triple-headed gamma camera, 154(ab)
regional cerebral blood flow during cerebrovascular stress, 141(ab)

Y

Yttrium-90, residence times and errors in patient absorbed-dose calculation, radioimmunotherapy, 264

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION

(REQUIRED BY 39 U.S.C. 3685)

1. A. Title of Publication: The Journal of Nuclear Medicine Technology.
   B. Publication Number: 966500.
2. Date of filing: September 25, 1997.
3. Frequency of issue: Quarterly.
3. A. Number of issues published annually: Four.
3. B. Annual Subscription price: $70 in U.S.A.; $75 in Canada and Pan-American countries; $80 elsewhere.
4. Complete mailing address of known office of publication: 1850 Samuel Morse Dr., Reston, VA 20190-5316.
5. Complete mailing address of the headquarters of general business offices of the publisher: 1850 Samuel Morse Dr., Reston, VA 20190-5316.
6. Full names and complete mailing address of publisher, editor, and managing editor: Publisher: Society of Nuclear Medicine, Inc., 1850 Samuel Morse Dr., Reston, VA 20190-5316; Editor: Susan Gilbert, 1850 Samuel Morse Dr., Reston, VA 20190-5316; Managing Editor: Dawn Murphy, 1850 Samuel Morse Dr., Reston, VA 20190-5316.
7. Owner: Society of Nuclear Medicine, Inc.,1850 Samuel Morse Dr. Reston, VA 20190-5316.
8. Known bondholders, mortgages and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages or other securities: None. Society of Nuclear Medicine, Inc., is a nonprofit corportation; there are no shareholders.
9. The purpose, function and nonprofit status of this organization and the exempt status for federal income tax purposes have not changed during the preceding 12 months.
10. Extent and nature of circulation: (A) Total number of copies printed; average during preceding 12 months—8,430; actual copies printed in September 1996—8,365; (B) 1. Paid circulation: Sales through dealers and carriers, street vendors and counter sales—none. Actual copies in September 1997—none. 2. Mail subscriptions: average—7,685; actual copies in September 1997—7,580; (C) Total paid circulation: average—7,685; actual copies in September 1997—7,580; (D) Free distribution by mail, carrier or other means: samples, complimentary, and other free copies; average—22; actual copies in September 1997—22; (E) Free distribution outside the mail, carriers or other means: average—none; actual copies in September 1997—none; (F) Total free distribution: average—22; actual copies in September 1997—22; (G) Total distribution: average—7,707; actual copies in September 1997—7,602; (H) 1. Copies not distributed; office use, left over, unaccounted for, spoiled after printing; average—723; actual copies in September 1997—763. Returns from news agents—none. (I) Total: average—8,301; actual copies in September 1997—8,365.
11. I certify that the statements made by me are correct and complete; (signed) John S. Childs, Director of Communication.